[A19-42] Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87
Last updated 21.06.2019
Commission awarded on 06.05.2019 by the Federal Joint Committee (G-BA).
Head and nerves
Children and adolescents with highly active or rapidly evolving relapsing-remitting multiple sclerosis (RRMS)
In one research question now also hint of added benefit in the category "health-related quality of life"; conclusion of dossier assessment A18-87 nonetheless unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-87||Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V||Commission completed|